Table 1.
Patient and Transplant Characteristics
| No post-HSCT CNS prophylaxis (n=238) | Received post-HSCT CNS prophylaxis (n=219) | P-value | |
|---|---|---|---|
|
| |||
| Center | <0.0001 | ||
| MDACC | 193 | 45 | |
| FHCRC | 38 | 161 | |
| RMC | 7 | 13 | |
|
| |||
| Median age at HSCT (range, years) | 38 (18 – 70) | 38 (19 – 76) | 0.78 |
|
| |||
| Sex | 0.34 | ||
| Female | 92 | 95 | |
| Male | 146 | 124 | |
|
| |||
| Lineage | 1.00 | ||
| B-cell | 201 | 188 | |
| T-cell | 33 | 30 | |
| Unknown | 4 | 1 | |
|
| |||
| Cytogenetic Risk Group | 0.65 | ||
| Good | 13 | 8 | |
| Intermediate | 86 | 87 | |
| Poor | 110 | 102 | |
| Unknown | 29 | 22 | |
|
| |||
| Status at HSCT | 0.002 | ||
| CR1 | 126 | 147 | |
| CR2 | 112 | 72 | |
|
| |||
| Pre-HSCT CNS Disease | 0.06 | ||
| None | 209 | 174 | |
| At Diagnosis | 15 | 23 | |
| At First Relapse | 11 | 18 | |
| Missing | 3 | 4 | |
|
| |||
| Preparative regimen | 0.89 | ||
| Myeloablative | 204 | 189 | |
| Non-myeloablative or RIC | 34 | 30 | |
|
| |||
| Allotype | 0.95 | ||
| HLA Matched-Related | 98 | 91 | |
| HLA Matched Unrelated | 86 | 80 | |
| HLA Mismatched-Related | 9 | 10 | |
| HLA Mismatched Unrelated | 45 | 38 | |
|
| |||
| Graft Source | 0.001 | ||
| Bone Marrow | 65 | 48 | |
| Peripheral Blood | 136 | 157 | |
| Cord Blood | 37 | 14 | |
|
| |||
| Relapse | 0.08 | ||
| Total | 60 | 74 | |
| CNS | 6 | 12 | |
|
| |||
| Graft-versus-Host Disease | |||
| Acute, grades II–IV | 100 | 156 | |
| Chronic, limited and/or extensive | 55 | 125 | |